ZEUS Scientific: American Expertise in Every American-Made Test
ZEUS Scientific Is a Proud American CompanyDoing our Part in the Fight Against COVID-19
ZEUS Scientific would like to wish all of you an enjoyable Independence Day and for those of you on the front line of this fight, we would like to thank you for your service throughout the COVID-19 pandemic. ZEUS has been doing our part in the fight against the SARS-CoV-2 virus in the U.S. and around the world by providing in vitro diagnostic (IVD) test systems for rapid and automated antibody testing. As a family-owned, SBA small business based in central New Jersey for over 40 years, ZEUS has allocated the majority of its resources to producing serological antibody tests to combat SARS-CoV-2. We have a long history of developing, manufacturing and delivering IVD kits for infectious and autoimmune disease testing. With over 125 FDA cleared assays in our menu, we continue to apply our expertise of developing tests to detect human antibodies to a number of different viruses including SARS-CoV-2. For decades, laboratories have trusted ZEUS and now is the time to maintain confidence in ZEUS as we all continue the battle against the COVID-19 pandemic and SARS-CoV-2 virus.
Options to Meet Customer Needs
ZEUS offers three separate SARS-CoV-2 antibody test systems across two methodologies: a rapid, lateral flow antibody test for detecting IgM/IgG and two automation-friendly ELISA antibody tests for detecting IgG/IgM/IgA or IgG alone. These tests provide flexibility to choose testing options. Our testing solutions are scalable to your needs including point of care, manual or automated applications. For automated applications, our ELISA assays have been validated on the Dynex DS2®, DSX® and Agility® platforms.
Unique Dual Antigen Approach
ZEUS recognizes the importance of selecting SARS-CoV-2 antigens for our assays and has conducted extensive in-house testing to make this determination. To optimize the performance of our tests, we employed a dual antigen approach by utilizing a combination of recombinant Spike Protein (S1) and recombinant Nucleocapsid (N-protein). By detecting antibodies directed against both the highly immunogenic N-protein and the S1-protein, which mediates attachment of the virus to human cells, our assays are optimized for superior sensitivity and specificity. ZEUS’s dual antigen approach is unique as most available tests are limited to either one antigen or the other.
All three ZEUS SARS-CoV-2 antibody tests have been validated according to EUA guidelines established by the FDA for serological assays. In addition, ZEUS has recently completed extensive performance testing of all three of our devices using the same three cohorts (total n=365) of clinically characterized patient samples. Through direct comparison of our three SARS-CoV-2 antibody tests, we demonstrated a correlation of over 97% across all three assays which provides confidence in all three of the ZEUS SARS-CoV-2 antibody tests.
Test with Confidence. Test with ZEUS.
ZEUS would like to again thank those of you on the front line of this fight for all that you have done throughout the COVID-19 pandemic. As an American-based company, we are committed to doing our part by providing continued assistance to laboratories with their SARS-CoV-2 testing needs. We will continue the battle to get through the COVID-19 pandemic together.
- ZEUS Rapid SARS-CoV-2 IgM/IgG: POC7801 (or order online!)
- ZEUS ELISA SARS-CoV-2 IgG: SM9Z7901G (or order online!)
- ZEUS ELISA SARS-CoV-2 Total Antibody: SM9Z7901 (or order online!)
Happy 4th of July!
The ZEUS Scientific FamilyBack Share